文献速递妇科

局部晚期宫颈癌及时治疗的延迟:妇科肿瘤专科就诊中的保险不平等

Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology.
PubMed 文献 · Am J Obstet Gynecol · 2025-02-20

该回顾性队列研究纳入2003至2023年单中心280例局部晚期宫颈癌患者,以活检后60天内开始治疗为及时治疗标准,发现仅37.1%患者及时治疗,医疗补助保险与治疗延迟独立相关(OR 2.42),延迟主要源于活检至分期阶段。

要点

  • 活检至治疗开始的中位时间为68.5天(四分位距52-104天),仅37.1%患者在60天内开始治疗。
  • 医疗补助保险患者延迟治疗风险约为私人保险者的2.42倍(OR 2.42,95%CI 1.18-4.93)。
  • 延迟主要归因于活检至分期的时间段,而非分期至治疗开始的时间段。

核心结论

  • 医疗补助保险与局部晚期宫颈癌及时治疗几率降低独立相关,延迟主要源于活检至分期阶段。
  • 作者认为这些发现强调需要针对性干预来解决保险相关的治疗启动障碍,可能包括筛查和处理未满足的健康相关社会需求和社会风险。

研究设计与样本

  • 回顾性队列研究,纳入2003至2023年单中心局部晚期宫颈癌患者280例。
  • 主要结局为及时启动治疗,定义为活检诊断后60天内开始治疗。
  • 采用多因素分析评估保险状态和其他人口学因素对治疗延迟的影响。

主要发现

  • 活检至治疗开始的中位时间为68.5天(四分位距52-104天),37.1%的患者及时启动治疗。
  • 单因素分析显示医疗补助保险患者延迟治疗的比值比显著升高(OR 2.76,95%CI 1.46-5.23)。
  • 单因素分析显示居住在社会脆弱性指数较高地理位置的患者延迟治疗比值比升高(第四分位OR 2.68,95%CI 1.22-5.85)。
  • 多因素分析显示医疗补助保险与私人保险相比独立关联于治疗延迟(OR 2.42,95%CI 1.18-4.93)。
  • 将治疗时间按活检至分期和分期至治疗开始分层后,延迟主要归因于活检至分期的时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer continues to disproportionately affect marginalized populations, with significant disparities in treatment and outcomes. Social determinants of health and insurance status have been associated with delays in treatment initiation, which can adversely affect clinical outcomes. OBJECTIVE: To determine the risk factors associated with delays in treatment initiation among patients with locally advanced cervical cancer and identify the time period of delay in treatment initiation. STUDY DESIGN: We conducted a retrospective cohort study of patients with locally advanced cervical cancer at a single institution between 2003 and 2023. The primary outcome was timely initiation of treatment, defined as treatment initiation within 60 days of diagnosis by biopsy. Multivariate analysis was used to assess the impact of insurance status and other demographic factors on treatment delays. RESULTS: Two hundred eighty patients were identified. The median time from biopsy to treatment initiation was 68.5 days (interquartile range, 52-104); 37.1% of patients received timely treatment initiation. Univariate analyses indicated patients with Medicaid had significantly increased odds of delayed treatment (odds ratio 2.76, 95% confidence interval 1.46-5.23) and living in a geographic location with a higher social vulnerability index (quartile 3 odds ratio 2.68 95% confidence interval 1.22-5.85). Multivariate analysis indicated that Medicaid was independently associated with delayed treatment compared to private insurance (odds ratio 2.42, 95% confidence interval 1.18-4.93). When time to treatment was stratified by time from biopsy to staging and time from staging to treatment start, delay was primarily attributable to time from biopsy to staging. In patients within the upper quartile of delay (>104 days), social risk factors including insurance-related issues and unmet social needs (eg, psychosocial distress, unstable housing, substance abuse) were identified as contributors to significant delays. CONCLUSION(S): Medicaid insurance was independently associated with lower odds of timely cervical cancer treatment, driven largely by delays between biopsy and staging. These findings underscore the need for targeted interventions to address insurance-mediated barriers to initiation of care, which may include screening and addressing unmet health-related social needs and social risks.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Liang J, Mvemba A, Swanson M, et al. Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology. Am J Obstet Gynecol. 2025. PMID: 39986339. doi:10.1016/j.ajog.2025.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。